Glycemic control and the first use of oral antidiabetic agents among patients with type 2 diabetes mellitus

References

• International Diabetes Federation. The Global Burden. IDF Diabetes Atlas: Fifth Edition. 2011. Available at: http://www.idf.org/diabetesatlas/5e/the-global-burden [Last accessed 11 July 2012]
   Google Scholar
• American Diabetes Association. Diabetes Statistics – American Diabetes Association. 2011. Available at: http://www.diabetes.org/diabetes-basics/diabetes-statistics/ [Last accessed 24 May 2011]
   Google Scholar
• U.S Department of Health and Human Services, Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. 2011. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf [Last accessed 11 July 2012]
   Google Scholar
• Dall TM, Mann SE, Zhang Y, et al. Distinguishing the economic costs associated with type 1 and type 2 diabetes. Popul Health Manag 2009;12:103-10
   PubMed Web of Science ®Google Scholar
• International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care 2009;32:1327-34
   PubMed Web of Science ®Google Scholar
• Executive summary: standards of medical care in diabetes – 2012. Diabetes Care 2012;35(Suppl 1):S4-10
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
   PubMed Web of Science ®Google Scholar
• Standards of medical care in diabetes – 2012. Diabetes Care 2011;35(Suppl 1):S11-63
   Web of Science ®Google Scholar
• Fowler MJ. Diabetes treatment, part 2: oral agents for glycemic management. Clin Diabetes 2007;25:131-4
   Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72
   PubMed Web of Science ®Google Scholar
• McKillop AM, Duffy NA, Lindsay JR, et al. Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects. Diabetes Res Clin Pract 2008;79:79-85
   PubMed Web of Science ®Google Scholar
• D’Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 1993;32:382-7
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• U.S Department of Health and Human Services, Agency for Healthcare Research and Quality. Research Activities. 2012 Jul p. 28. Report No.: 383
   Google Scholar
• Sify Technologies Ltd. Men’s Health Sify Health. 2012. Available at: http://health.sify.com/tag/mens-health/ [Last accessed 12 July 2012]
   Google Scholar
• Gale EA, Gillespie KM. Diabetes and gender. Diabetologia 2001;44:3-15
   PubMed Web of Science ®Google Scholar
• Egan BM, Shaftman SR, Wagner CS, et al. Demographic differences in the treatment and control of glucose in type 2 diabetic patients: implications for health care practice. Ethn Dis 2012;22:29-37
   PubMed Web of Science ®Google Scholar
• Rozenfeld Y, Hunt JS, Plauschinat C, et al. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care 2008;14:71-5
   PubMed Web of Science ®Google Scholar
• Saad L. Chronic Illness Rates Swell in Middle Age, Taper Off After 75. Gallup Wellbeing. 2011. Available at: http://www.gallup.com/poll/147317/chronic-illness-rates-swell-middle-age-taper-off.aspx [Last accessed 13 July 2012]
   Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65
   Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53
   Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86
   Google Scholar
• Collins FM. Current treatment approaches to type 2 diabetes mellitus: successes and shortcomings. Am J Manag Care 2002;8(16 Suppl):S460-71
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones. Diabetologia 2008;51:8-11
   PubMed Web of Science ®Google Scholar
• Simonson G, Cuddihy R, Reader D, et al. International Diabetes Center treatment of type 2 diabetes glucose algorithm. Diabetes Management 2011;1:175-89
   Google Scholar
• Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728-40
   PubMed Web of Science ®Google Scholar
• Cui Z, Zhao Y, Novick D, et al. Predictors of duloxetine adherence and persistence in patients with fibromyalgia. J Pain Res 2012;5:193-201
   PubMedGoogle Scholar
• Song X, Sander SD, Varker H, et al. Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation. Am J Cardiovasc Drugs 2012;12:245--53
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
   PubMed Web of Science ®Google Scholar
• Marre M. Before oral agents fail: the case for starting insulin early. Int J Obes Relat Metab Disord 2002;26(Suppl 3):S25-30
   PubMedGoogle Scholar
• Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005;65:385-411
   PubMed Web of Science ®Google Scholar
• Gascón JJ, Sánchez-Ortuño M, Llor B, et al.; Treatment Compliance in Hypertension Study Group. Why hypertensive patients do not comply with the treatment: results from a qualitative study. Fam Pract 2004;21:125-30
   PubMed Web of Science ®Google Scholar
• Ghods AJ, Nasrollahzadeh D. Noncompliance with immunosuppressive-medications after renal transplantation. Exp Clin Transplant 2003;1:39-47
   PubMedGoogle Scholar
• Cramer JA, Benedict A, Muszbek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 2008;62:76-87
   PubMed Web of Science ®Google Scholar
• Desai NR, Shrank WH, Fischer MA, et al. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med 2012;125:302.e1-7
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2008. Diabetes Care 2008;31(Suppl 1):S12-54
   PubMed Web of Science ®Google Scholar
• Delamater AM. Improving patient adherence. Clin Diabetes 2006;24:71-7
   Google Scholar